Review Reports
- Pamela Acha1,
- Mar Mallo1,2 and
- Francesc Solé1,2,*
Reviewer 1: Margaret T. Kasner Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
the authors present an updated review of MDS with isolated 5q deletion.
It references the newest WHO and ICC classifications and reviews additional genetic abnormalities.
It is comprehensive and a useful resource.
It appears not to be written by a native English speaker and could benefit from minor edits.
Author Response
Reviewer 1 comments:
The authors present an updated review of MDS with isolated 5q deletion.
It references the newest WHO and ICC classifications and reviews additional genetic abnormalities.
It is comprehensive and a useful resource.
Point 1: It appears not to be written by a native English speaker and could benefit from minor edits
Response 1: The manuscript has been reviewed by a native speaker and has been corrected accordingly.
Reviewer 2 Report
This is a well written review on MDS with isolated del5q with a focus on additional molecular alterations already also adressing the newly published classifications and prognostic tools.
Some points for possible amendments:
Although "clinical relevance" is mentioned as topic in the abstract this should be further elaborated: how often during the course of the disease should genetics be monitored ? should all methods be applied in all circumstances? which consequences should be taken upon detection of clonal evolution ?
some suggestions for Figure 1:
in upper part add a mention of elucidation of pathomechansims (ref 27-29)
when mentioning allelic state of tp53 - also include initial data on tp53
only selected items have references: need to give references to other points as well, to have a clearer picture probably only ref number of ref list
Minor points:
Line 39: ref 3 is ICC not WHO
Line 196 Prognostic impact
Author Response
Reviewer 2 comments:
This is a well written review on MDS with isolated del5q with a focus on additional molecular alterations already also adressing the newly published classifications and prognostic tools.
Some points for possible amendments:
Point 1: Although "clinical relevance" is mentioned as topic in the abstract this should be further elaborated: how often during the course of the disease should genetics be monitored? should all methods be applied in all circumstances? which consequences should be taken upon detection of clonal evolution ?
Response 1: New information regarding follow-up approach has been added to the manuscript (lines 215-219).
Point 2: Some suggestions for Figure 1:
In upper part add a mention of elucidation of pathomechansims (ref 27-29)
When mentioning allelic state of tp53 - also include initial data on tp53
Only selected items have references: need to give references to other points as well, to have a clearer picture probably only ref number of ref list
Response 2: Related to Figure 1:
- A timeline point about pathomechanisms has been added.
- Regarding TP53, Jädersten et al study, which revealed the poor response of MDS 5q patients with TP53 mutation to lenalidomide treatment, has been added.
- Lastly, reference numbers have been added.
Point 3: Line 39: ref 3 is ICC not WHO
Response 3: References have been redistributed.
Point 4: Line 196 Prognostic impact
Response 4: The header from (old) line 196 has been changed.